Conv. Plasma
Nigella Sativa

All sotrovimab studies
Meta analysis
study COVID-19 treatment researchSotrovimabSotrovimab (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 75% Improvement Relative Risk Hospitalization, COVID-19 60% Hospitalization, all cause -21% Sotrovimab  Goodwin et al.  EARLY TREATMENT Is early treatment with sotrovimab beneficial for COVID-19? Retrospective 505 patients in the United Kingdom (Dec 2021 - Feb 2022) Lower mortality (p=0.55) and hospitalization (p=0.35), not sig. Goodwin et al., PLOS ONE, March 2023 Favors sotrovimab Favors control

Evaluation of outpatient treatment for non-hospitalised patients with COVID-19: The experience of a regional centre in the UK

Goodwin et al., PLOS ONE, doi:10.1371/journal.pone.0281915
Mar 2023  
  Source   PDF   All   Meta
Sotrovimab for COVID-19
39th treatment shown to reduce risk in May 2023
*, now known with p = 0.0017 from 22 studies, recognized in 36 countries. Efficacy is variant dependent.
Lower risk for hospitalization.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Retrospective 604 outpatients in the UK, showing lower risk of hospitalization with sotrovimab treatment, without statistical significance due to the small number of hospitalizations.
Efficacy is variant dependent. In Vitro studies predict lower efficacy for BA.1 Liu, Sheward, VanBlargan, BA.4, BA.5 Haars, XBB.1.9.3, XBB.1.5.24, XBB.2.9, CH.1.1 Pochtovyi, and no efficacy for BA.2 Zhou, ХВВ.1.9.1, XBB.1.16, BQ.1.1.45, and CL.1 Pochtovyi. US EUA has been revoked.
Study covers molnupiravir and sotrovimab.
risk of death, 75.0% lower, RR 0.25, p = 0.55, treatment 0 of 169 (0.0%), control 2 of 336 (0.6%), NNT 168, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of hospitalization, 60.2% lower, RR 0.40, p = 0.35, treatment 2 of 169 (1.2%), control 10 of 336 (3.0%), NNT 56, COVID-19 related.
risk of hospitalization, 21.5% higher, RR 1.21, p = 0.69, treatment 11 of 169 (6.5%), control 18 of 336 (5.4%), all cause.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Goodwin et al., 15 Mar 2023, retrospective, United Kingdom, peer-reviewed, 3 authors, study period 22 December, 2021 - 20 February, 2022. Contact:
This PaperSotrovimabAll
Evaluation of outpatient treatment for non-hospitalised patients with COVID-19: The experience of a regional centre in the UK
Amanda T Goodwin, Jonathan S Thompson, Ian P Hall
PLOS ONE, doi:10.1371/journal.pone.0281915
Introduction Antivirals, such as molnupiravir, and SARS-CoV-2 neutralising monoclonal antibodies (nMAbs), such as sotrovimab, reduced the risk of hospitalisation and death in clinical trials of high-risk non-hospitalised patients with Covid-19. However, the real-world benefits of these drugs are unclear. Aims To evaluate the characteristics and outcomes of high-risk patients referred for outpatient antiviral or nMAb treatment for symptomatic Covid-19. Methods The records of patients referred to a large UK Covid Medicines Delivery Unit (CMDU) over nine weeks (December 2021-February 2022) were reviewed. Data were collected on demographics, referral indications, vaccination, deprivation, treatment, complications, hospital admission, and mortality. Results 1820 patients were referred to the CMDU, with 604 (33.2%) suitable for further assessment. 169 patients received sotrovimab, 80 patients received molnupiravir, 70 patients declined treatment, and 266 were ineligible for treatment because of resolving symptoms. There were trends towards higher proportions of female and white patients, lower deprivation scores, and malignancy-or transplant-related indications in the groups receiving treatment compared with untreated patients. Covid-19-related hospitalisations occurred in 1.2% of the treated group and 3.0% of the untreated group indicating a potential treatment effect, however Covid-related hospitalisations were lower than reported in the original clinical trials (2.2% compared with 7-10%). Conclusion The referral pathways for outpatient treatment of Covid-19 are inefficient, and the UK system may not be serving all groups equitably. Hospitalisation with Covid-19 was rare
Bernal, Da Silva, Musungaie, Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients, N Eng J Med, doi:10.1056/NEJMoa2116044
Bruel, Hadjadj, Maes, Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies, Nat Med, doi:10.1038/s41591-022-01792-5
Chavarot, Melenotte, Amrouche, Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection, Kidney Int, doi:10.1016/j.kint.2022.04.003
Deng, Heybati, Ba, Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis, Infection, doi:10.1007/s15010-022-01825-8
Dhand, Okumura, Wolfe, Sotrovimab for treatment of COVID-19 in solid organ transplant recipients, Transplantation, doi:10.1097/TP.0000000000004136
Gupta, Gonzales-Rojas, Juarez, Early treatment for Covid-19 with SARS-CoV-2 Neutralizing antibody sotrovimab, N Engl J Med, doi:10.1056/NEJMoa2107934
Gupta, Gonzales-Rojas, Juarez, Effect of sotrovimab on hospitalisation or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial, JAMA, doi:10.1001/jama.2022.2832
Nhs England, Statistical work areas: COVID-19 therapeutics (antivirals, neutralising monoclonal antibodies, and interleukin 6 inhibitors
Scobie, Morris, Quality and inequality: digging deeper
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop